Industry Commentary
BioAlberta works with policymakers at all levels for a coordinated approach to setting public policy initiatives and ensuring the life sciences industry’s critical issues are well represented.
Through our Advocacy and Policy Committee, BioAlberta focuses on legislative and regulatory policy at the provincial level.
However, we also work with partner life science organizations across the country to support federal regulatory issues. Our Advocacy and Policy Committee is divided into subcommittees to answer the unique needs of each of the life science sectors.
Priority activities include:
- Coverage of critical legislation and regulatory policy
- Educating public officials about biotechnology
- Encouraging greater support for life sciences entrepreneurship
- Simplifying the regulatory environment, among other issues
Commentary
Response to Health Canada on the National Strategy for High-Cost Drugs for Rare Diseases
Response to Health Canada on the National Stratgy on High Cost Drugs for Rare Disease
View more
Policy Development
View all
Response to Health Canada on the National Strategy for High-Cost Drugs for Rare Diseases
Response to Health Canada on the National Strategy for High-Cost Drugs for Rare Diseases
Response to Health Canada on the National Stratgy on High Cost Drugs for Rare Disease
View more